Clinical Pharmacology & Biopharmaceutics
Open Access

Cardiovascular pharmacology; Antihypertensive drugs; Personalized medicine; Hypertension; Pharmacogenomics; Drug metabolism; Genetic biomarkers; Blood pressure regulation; ACE inhibitors; Beta-blockers

Introduction

Hypertension, a major risk factor for cardiovascular diseases (CVD), continues to be a leading cause of morbidity and mortality worldwide. Traditional approaches to managing hypertension often involve a one-size-fits-all strategy with medications such as diuretics, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and calcium channel blockers. However, these treatments do not offer the same level of efficacy for every patient, and in some cases, adverse effects or poor adherence can limit their effectiveness [1-5].

Emerging therapeutics in cardiovascular pharmacology, combined with advances in personalized medicine, offer a promising approach to improving antihypertensive strategies. Personalized medicine involves tailoring medical treatment to individual genetic, environmental, and lifestyle factors, allowing for more effective and safer therapeutic interventions. In hypertension management, this could mean adjusting drug choice and dosage based on genetic biomarkers that influence drug metabolism and response. Pharmacogenomics, the study of genetic factors that affect drug response, plays a pivotal role in this approach. By identifying specific genetic variations that affect the action of antihypertensive drugs, clinicians can provide more individualized treatments that optimize therapeutic outcomes. As our understanding of the molecular mechanisms underlying hypertension expands, personalized antihypertensive strategies are poised to become a central component of cardiovascular care, potentially reducing the burden of hypertension-related complications [6-10].

Discussion

The concept of personalized antihypertensive therapy is gaining traction, particularly with the discovery of genetic factors that influence individual responses to antihypertensive drugs. A major focus has been on the identification of genetic variants that affect the pharmacodynamics and pharmacokinetics of commonly used antihypertensive medications. For example, variations in the ACE gene can influence the efficacy of ACE inhibitors, which are commonly prescribed for hypertension and heart failure. Patients with certain polymorphisms in this gene may have a stronger or weaker response to these medications. Similarly, genetic variations in the beta-adrenergic receptor (ADRβ) gene can affect the response to beta-blockers, which are commonly used to reduce heart rate and lower blood pressure. By identifying these genetic markers, healthcare providers can better predict which antihypertensive medications will be most effective for an individual, potentially reducing the need for trial-and-error treatment strategies.

Pharmacogenomics also aids in understanding why some patients experience side effects or poor drug efficacy. For instance, variations in the CYP450 enzyme family, which is responsible for metabolizing many antihypertensive drugs, can lead to differences in drug levels and, consequently, therapeutic outcomes. In patients with altered CYP450 enzyme activity, the standard dosage of a drug may be too high or too low, resulting in either toxicity or inadequate blood pressure control. Personalized antihypertensive therapy, guided by pharmacogenomic data, can optimize drug dosing, reduce side effects, and improve patient compliance.

Moreover, the advent of biomarker-based approaches is further enhancing personalized hypertension treatment. Biomarkers such as circulating microRNAs, pro-inflammatory cytokines, and renal sodium transport proteins are being explored as potential indicators of blood pressure regulation and cardiovascular risk. These biomarkers may provide more precise measurements of hypertension pathophysiology, allowing clinicians to select the most appropriate antihypertensive drugs based on an individual's specific biomarker profile. Additionally, combination therapies that target multiple pathways involved in blood pressure regulation (e.g., the renin-angiotensin-aldosterone system, sympathetic nervous system, and endothelial function) could benefit from a personalized approach, where the combination of drugs is tailored to the patient’s genetic and molecular profile.

Despite the promising potential of personalized antihypertensive strategies, there are several challenges to be addressed. One major challenge is the integration of pharmacogenomic testing into routine clinical practice. While pharmacogenetic testing is becoming more accessible, it is not yet widely adopted in the clinical setting, largely due to cost, availability of tests, and a lack of standardized guidelines for the interpretation of results. Moreover, the complexity of hypertension as a multifactorial condition, influenced by genetics, environment, and lifestyle, requires a holistic approach. The personalization of treatment will need to take into account these multiple factors, including socioeconomic status, diet, physical activity, and adherence to medication. Furthermore, more extensive research is needed to identify additional genetic and molecular factors involved in hypertension, as well as to determine the long-term outcomes of personalized antihypertensive treatments.

Conclusion

Emerging therapeutics in cardiovascular pharmacology, combined with the growing field of personalized medicine, represent a transformative opportunity for the treatment of hypertension. By incorporating genetic, molecular, and environmental factors into the decision-making process, personalized antihypertensive strategies hold the promise of improving therapeutic outcomes, reducing side effects, and enhancing patient satisfaction. Pharmacogenomic data can guide clinicians in selecting the most effective and safe medications, minimizing the trial-and-error approach that has historically plagued hypertension management. While challenges remain in terms of integrating personalized medicine into clinical practice and further validating pharmacogenomic markers, the future of antihypertensive therapy is increasingly moving toward precision medicine. As research continues to uncover genetic and molecular factors influencing blood pressure regulation, the potential for personalized therapies will likely revolutionize the way hypertension is managed, ultimately improving patient outcomes and reducing the burden of cardiovascular diseases worldwide.

References

1. Kumar A, Kini SG, Rathi E (2021) A recent appraisal of artificial intelligence and in silico ADMET prediction in the early stages of drug discovery. Mini Rev Med Chem 21: 2788-2800.

   Indexed at, Google Scholar, Crossref

2. Norrby PO (2019) Holistic models of reaction selectivity. Nature 571: 332-333.

   Indexed at, Google Scholar, Crossref

3. Cramer RD, Bunce JD, Patterson DE, Frank IE (1988) Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Mol Inform 7: 18-25.

   Google Scholar, Crossref

4. Li Y, Zhang L, Wang Y (2022) Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor. Nat Commun 13

   Indexed at, Google Scholar, Crossref

5. Zhang D, Luo G, Ding X, Lu C (2012) Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharm Sin B 2: 549-561.

   Google Scholar

6. Skalic M, Jiménez J, Sabbadin D, De Fabritiis G (2019) Shape-based generative modeling for de novo drug design. J Chem Inf Model 59: 1205-1214.

   Indexed at, Google Scholar, Crossref

7. T, Correia J, Pereira V, Rocha M (2021) Generative deep learning for targeted compound design. Sousa J Chem Inf Model 61: 5343-5361.

   Indexed at, Google Scholar, Crossref

8. Tran TT, Tayara H, Chong KT (2023) Artificial intelligence in drug metabolism and excretion prediction: recent advances, challenges, and future perspectives. Pharmaceutics 15

   Indexed at, Google Scholar, Crossref

9. Dara S, Dhamercherla S, Jadav SS, Babu CM, Ahsan MJ (2022) Machine learning in drug discovery: a review. Artif Intell Rev 55: 1947-1999.

   Indexed at, Google Scholar, Crossref

10. Sahu A, Mishra J, Kushwaha N. (2022) Artificial intelligence (AI) in drugs and pharmaceuticals. Comb Chem High Throughput Screen. 25: 1818-1837.

    Indexed at, Google Scholar, Crossref